IRON - NASDAQ
Disc Medicine, Inc.
$70.35
-2.3%Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
At a Glance
Live Snapshotiron
Total Non-Current Liabilities
Last Annual Value
30.41M
3-Year CAGR
209%
5-Year CAGR
42%
10-Year CAGR
19%
Disc Medicine, Inc. Competitors Analysis of Total Non-Current Liabilities
| Company | Total Non-Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 Disc Medicine, Inc. NASDAQ:IRON | 30.41M | 176.7% | -26.6% | N/A | |
 Tarsus Pharmaceuticals, Inc. NASDAQ:TARS | 83.04M | 38.0% | 160.0% | N/A | |
 Celcuity Inc. NASDAQ:CELC | 321.85M | 105.2% | 85.4% | N/A | |
 CG Oncology, Inc. Common stock NASDAQ:CGON | 8.15M | 216.6% | -8.1% | N/A | |
 Apogee Therapeutics, Inc. NASDAQ:APGE | 5.34M | 78.9% | N/A | N/A | |
 Adaptive Biotechnologies Corporation NASDAQ:ADPT | 197.82M | -9.3% | -0.8% | N/A | |
 Legend Biotech Corporation NASDAQ:LEGN | 95.20M | -37.0% | -5.2% | N/A | |
 Scholar Rock Holding Corporation NASDAQ:SRRK | 103.36M | 24.9% | 8.7% | 5.6% |
Disc Medicine, Inc. Fair Value Envelope
Related Guides
Continue your IRON research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.